Subtype
WHO Grade 2 Glioma
CI-CAN-00007115Explore in graph →
Non-malignant84 active trials28 evidence items
- NCIt
- C132505
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007115Explore in graph →
Clinical trials
255 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05297864 | PARP Inhibition for Gliomas (PI-4G or π4g)(OU-SCC-PI-4G) | terminated | Phase 2 | 15 | University of OklahomaOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT01247922 | Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 | terminated | Phase 2 | 4 | OSI PharmaceuticalsINDUSTRY | 3 | Dec 6, 2024 | clinicaltrials |
| NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | terminated | Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT03727841 | Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2022 | clinicaltrials |
| NCT00003479 | Antineoplaston Therapy in Treating Patients With Ependymoma | terminated | Phase 2 | 9 | Burzynski Research InstituteOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT03906448 | FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma(FORWARD) | terminated | Phase 2 | 1 | University of FloridaOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02684071 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors | terminated | Phase 2 | 3 | Nicklaus Children's Hospital f/k/a Miami Children's HospitalOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | terminated | Phase 2 | 43 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00003472 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma | terminated | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00360828 | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas | terminated | Phase 2 | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01088035 | Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma | terminated | Phase 2 | 75 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 2, 2015 | clinicaltrials |
| NCT00389090 | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | terminated | Phase 2 | 32 | Keryx / AOI Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 9, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials